Dasatinib monohydrate (BMS-354825 monohydrate) is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Ki values of 16 pM and 30 pM for Src and Bcr-Abl, respectively
*The following content is generated by AI and is for reference only.
Overview
Dasatinib monohydrate is a crystalline form of the tyrosine kinase inhibitor used in oncology. Synthesized via multi-step organic coupling, its molecular formula is C21H27N7O·H2O with CAS No. 864015-90-3.
Application
- Treatment of chronic myeloid leukemia (CML) resistant to imatinib.
- Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
- R&D of second-generation BCR-ABL inhibitors for targeted therapy.
Precautions
Store below 25°C in dry conditions away from light. Strictly adhere to clinical dosage protocols to avoid pleural effusion and thrombocytopenia risks.